Gen-Probe Launches CE-Marked MDx Platform in Europe, Targeting Lower-Volume Labs
December 02, 2010
Gen-Probe Launches CE-Marked MDx Platform in Europe, Targeting Lower-Volume Labs
The new platform, called Panther, is expected to help Gen-Probe capture market share in the area of molecular testing at mid- and low-volume clinical laboratories, clinics, and physicians' offices as it competes with platforms from companies such as Roche, Qiagen, Cepheid, and Becton Dickinson.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Gen-Probe to Add Real-Time PCR Capability to Next-Gen Panther MDx Platform
January 19, 2012 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - On Heels of FDA Approval, Cepheid's Xpert CT/NG Test Performs Well in Multi-Center Clinical Study
March 14, 2013 / PCR Insider - Hologic's Gen-Probe Wins Judgment in IP Suit Against BD, but Dispute Remain Unresolved
October 4, 2012 / PCR Insider - Gen-Probe to Serve as 'Cornerstone' of Hologic's MDx Franchise, Primarily Through STD Test Offerings
May 3, 2012 / PCR Insider